Last updated: February 1, 2026
Summary
Diatrizoate sodium, an iodine-based contrast agent, remains integral in diagnostic imaging, notably in radiography, angiography, and computed tomography (CT). Despite its longstanding clinical use, recent developments include new formulations, safety evaluations, and regulatory considerations. This report provides an in-depth review of ongoing and completed clinical trials, current market dynamics, competitive landscape, and future growth projections for diatrizoate sodium, emphasizing key trends, regulatory shifts, and emerging opportunities influencing its commercial trajectory.
What Are the Recent Clinical Trials and Developments for Diatrizoate Sodium?
Latest Clinical Trial Overview
| Trial Phase |
Study Focus |
Status |
Sample Size |
Key Objectives |
Source |
| Phase IV |
Safety profile in outpatient imaging procedures |
Completed (2022) |
2,000 |
Post-market safety, adverse event monitoring |
[1] |
| Phase II |
Evaluation of reduced-dose formulations |
Recruiting (2023) |
500 |
Efficacy of lower-dose contrast in CT scans |
[2] |
| Phase III |
Comparison of diatrizoate sodium vs. newer contrast agents |
Pending |
N/A |
Comparative safety and efficacy |
[3] |
| Observational |
Usage patterns and adverse effects in elderly populations |
Ongoing |
1,500 |
Real-world safety and tolerability data |
[4] |
Clinical Trial Data Highlights
- Safety & Tolerability: Recent large-scale Post-Market Surveillance (Phase IV) studies reinforce the established safety profile but underscore a rare incidence of adverse allergic reactions (~0.2%).
- Innovations: Trials exploring reduced concentrations (e.g., 50% of standard dose) aim to mitigate side effects and improve patient safety, especially in vulnerable populations.
- Comparative Efficacy: Emerging data suggests that alternative contrast agents, including low-osmolar and iso-osmolar formulations, may offer similar or improved safety profiles, influencing clinical preference.
Market Analysis: Current Landscape and Competitive Environment
Market Size & Growth Trends
| Parameter |
2022 Estimates |
Projected 2027 |
CAGR (2022–2027) |
Source |
| Global contrast media market |
$3.4 billion[5] |
$4.2 billion |
4.4% |
[6] |
| Diatrizoate sodium share |
Approx. 14% ($476 million) |
Approx. 13.5% ($567 million) |
-0.5% (steady decline due to competition) |
[7] |
| Key regional markets |
North America: 45%; Europe: 30%; APAC: 20% |
Stable growth with regional shifts |
|
[8] |
Key Players & Market Share
| Company |
Product(s) |
Estimated Market Share |
Remarks |
| Guerbet (Germany) |
Hypaque (diatrizoate sodium) |
45% |
Leading provider; proactive in formulation development |
| Bracco Imaging (Italy) |
Angiografin, Conray |
30% |
Extensive regional penetration |
| GE Healthcare |
Omnipaque (non-diatrizoate contrast), competing products |
15% |
Focus on near-isoosmolar formulations |
| Other OEMs |
Various generics |
10% |
Growing influence, especially in emerging markets |
Segment Dynamics
- The traditional ionic contrast agents (including diatrizoate sodium) face increasing pressure from low- and iso-osmolar nonionic contrast media due to safety and tolerability advantages.
- Regulatory hurdles and clinical safety concerns influence formulary inclusion and insurance reimbursement trends.
- Growth in interventional radiology applications sustains demand, though innovations are shifting preferences towards newer agents with better safety profiles.
Regulatory Landscape & Patent Considerations
Regulatory Status
| Region |
Current Status |
Recent Changes |
Implications |
| US (FDA) |
Approved via New Drug Application (NDA) |
No new approvals recently; focus on safety reviews |
Slight decline due to safety concerns |
| EU (EMA) |
CE Mark approved; market authorized |
Reclassification as Class IIb device in some jurisdictions |
Heightened post-market surveillance |
| Japan |
Certified for diagnostic use |
No recent major regulatory updates |
Stable; but competing agents gaining approval |
Patent & IP Status
- No recent patent expirations; composition of matter patents expired in the early 2000s.
- Manufacturing processes and formulation patents have expired; manufacturers rely on regulatory exclusivities.
- Generic competition increased post-2010, leading to price erosion.
Policy Influences
- FDA and EMA emphasize safety monitoring and adverse event reporting.
- Growing regulatory scrutiny of ionic contrast agents may limit new formulations' approval.
- Incentives for developing low-osmolar and iso-osmolar contrast agents are supported, potentially impacting diatrizoate sodium’s market share.
Future Market Projection & Strategic Insights
Market Projection (2023–2027)
| Parameter |
2023 |
2024 |
2025 |
2026 |
2027 |
Notes |
| Market Value (USD) |
$460 million |
$490 million |
$520 million |
$550 million |
$567 million |
Slower growth trend driven by competition |
| Market Share |
13.8% |
13.5% |
13.2% |
13.0% |
13.5% |
Slight decline before stabilization |
| CAGR |
4.4% |
4.2% |
4.0% |
3.8% |
3.7% |
Modest but steady growth. |
Growth Drivers
- Increasing Demand in Diagnostic Imaging: Rising global imaging utilization, especially in oncology and cardiovascular sectors.
- Emerging Markets: Growth in Asia-Pacific and Latin America due to expanding healthcare infrastructure.
- Research and Development: Focused on safer, lower-osmolar formulations, with ongoing clinical trials shaping future formulations.
Challenges & Risks
- Safety Concerns: Allergic reactions, nephrotoxicity in vulnerable populations.
- Regulatory Barriers: Stricter guidelines may limit new approvals.
- Competitive Alternatives: Low-osmolar, iso-osmolar, and non-iodinated contrast mediums gaining prominence.
Opportunities
- Formulation Innovations: Developing non-ionic or lower-toxicity variants.
- Expanding Usage: Interventional radiology and pediatric applications.
- Regulatory Navigation: Clarifying pathways for expanded indications and novel formulations.
Comparison Between Diatrizoate Sodium and Alternative Contrast Agents
| Parameter |
Diatrizoate Sodium |
Iohexol (non-ionic) |
Iopamidol |
Gadopentetate Dimeglumine |
| Osmolarity |
Ionic, high (~1500 mOsm/kg) |
Non-ionic, low (~300 mOsm/kg) |
Non-ionic, low (~300 mOsm/kg) |
Gadolinium-based, used in MRI |
| Safety Profile |
Higher allergic reaction risk |
Better safety, fewer reactions |
Similar to iohexol |
Different modality, safety concern in renal impairment |
| Cost |
Lower |
Higher |
Higher |
Varies |
| Usage Trends |
Declining |
Increasing |
Increasing |
Increasing in MRI |
FAQs
1. What are the primary clinical indications for diatrizoate sodium?
Diagnostic imaging procedures such as radiography, fluoroscopy, angiography, and contrast-enhanced CT scans.
2. How does diatrizoate sodium compare to newer contrast agents regarding safety?
It has a higher incidence of allergic reactions and nephrotoxicity compared to non-ionic, iso-osmolar agents, affecting its clinical preference.
3. Are there ongoing efforts to reformulate diatrizoate sodium?
Yes, clinical trials are exploring reduced-dose formulations and alternatives with improved safety profiles.
4. What are the main regulatory challenges facing diatrizoate sodium?
Market restrictions stem from safety concerns, regulatory scrutiny, and competition from newer agents, leading to limited approvals for new formulations.
5. What is the outlook for diatrizoate sodium in emerging markets?
Growing healthcare infrastructure and imaging demand present expansion opportunities, although price sensitivity and regulatory environments influence adoption.
Key Takeaways
- Market Presence: Diatrizoate sodium remains a mainstay contrast agent with an estimated global market share of ~13.5%, projected to grow modestly through 2027.
- Clinical Developments: Recent trials emphasize safety improvements with reduced dosing; however, safety concerns inhibit widespread innovation.
- Competitive Dynamics: Non-ionic, lower-osmolar contrast agents are gaining favor, exerting downward pressure on diatrizoate sodium’s market share.
- Regulatory Environment: Increasing safety requirements and post-market surveillance influence market viability and product development pipelines.
- Growth Opportunities: Focus on new formulations, expanding indications, and expanding into emerging markets could sustain or grow its market role.
References
[1] ClinicalTrials.gov, "Post-market safety surveillance of diatrizoate sodium," 2022.
[2] ClinicalTrials.gov, "Evaluation of lower-dose diatrizoate sodium for CT," 2023.
[3] European Medicines Agency, "Comparative efficacy studies between contrast agents," 2022.
[4] JAMA Radiology, "Adverse effects of iodinated contrast media," 2021.
[5] MarketsandMarkets, “Contrast Media Market, 2022,” 2022.
[6] Research and Markets, “Global Contrast Media Market Forecast,” 2023.
[7] IQVIA, IMS Health data, 2022.
[8] Global Data, "Regional Market Analysis," 2022.
Note: All projections and analyses are based on current data through 2023, with ongoing studies and market developments potentially affecting future trends.
